Selective GPR55 antagonist. Inhibits LPI-induced Ca2+
= 0.21 μ
M in HEK-GPR55 cells), ERK1/2 phosphorylation and GPR55-mediated transcription factor activation. Displays weak inhibition of acetylcholinesterase, μ
-opioid receptor, KCNH2 and hERG. Decreases LPI-induced GPR55 internalization. Reduces experimental intestinal inflammation in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl et al.
The GPR55 antagonist CID16020046 protects against intestinal inflammation.
Stančić et al.
The citations listed below are publications that use Tocris products. Selected citations for CID 16020046 include:
Showing Results 1 - 1 of 1